IP Library Patent Application 10575253
Patent Application
App. No. 10/575,253

Genomically modified cell neutralized to serum-free system

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/575,253
Abstract

Development of a host cell capable of producing a glycoprotein composition such as an antibody composition which is useful in development of medicaments is desired. The present invention provides a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium and a process for producing a glycoprotein composition using the cell.

Claims (32)

1 . A cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium.

2 . The cell according to claim 1 , wherein all of alleles on a genome encoding an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain are knocked out, and wherein the cell is naturalized in a serum-free medium.

3 . The cell according to claim 1 , wherein an exon region containing an initiation codon of the genomic gene encoding an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is deleted, and wherein the cell is naturalized in a serum-free medium.

4 . The cell according to claim 1 , wherein the enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is α-1,6-fucosyltransferase.

5 . The cell according to claim 4 , wherein the α-1,6-fucosyltransferase is a protein encoded by a DNA selected from the following (a) or (b):

(a) a DNA comprising the nucleotide sequence represented by SEQ ID NO:1;

(b) a DNA which hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and encodes a protein having α-1,6-fucosyltransferase activity.

6 . The cell according to claim 4 , wherein the α-1,6-fucosyltransferase is a protein selected from the group consisting of the following (a), (b) and (c):

(a) a protein comprising the amino acid sequence represented by SEQ ID NO:5;

(b) a protein consisting of an amino acid sequence in which one or more amino acid(s) is/are deleted, substituted, inserted and/or added in the amino acid sequence represented by SEQ ID NO:5 and having α-1,6-fucosyltransferase activity;

(c) a protein consisting of an amino acid sequence which has at least 80% amino acid sequence homology to the amino acid sequence represented by SEQ ID NO:5 and having α-1,6-fucosyltransferase activity.

7 . The cell according to claim 1 , which is resistant to a lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain.

8 . The cell according to claim 7 , wherein said resistance is resistance in which the cell survives at a higher ratio than a cell in which the genomic gene has not been knocked out when the cells are cultured in a medium containing the lectin which recognizes a sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain.

9 . The cell according to claim 1 , wherein the serum-free medium is a protein-free medium.

10 . The cell according to claim 1 , which comprises a gene encoding a glycoprotein.

11 . The cell according to claim 10 , wherein the glycoprotein is a glycoprotein having no sugar chain structure in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain.

12 . The cell according to claim 10 , wherein the glycoprotein is an antibody.

13 . The cell according to claim 12 , wherein the antibody belongs to an IgG class.

14 . A process for producing a glycoprotein composition, which comprises using the cell according to claim 1 .

15 . A process for producing a glycoprotein composition, which comprises culturing the cell according to claim 1 in a medium to form and accumulate the glycoprotein composition in the culture, and recovering and purifying the glycoprotein composition from the culture.

16 . The process for producing a glycoprotein composition according to claim 14 or 15 , wherein the process is carried out by batch culture, fed-batch culture or perfusion culture.

17 . The process according to claim 14 or 15 , wherein at least one selected from a nutrient factor and a physiologically active substance is added to the medium during culturing.

18 . The process according to claim 17 , wherein the nutrient factor is at least one selected from a glucose, an amino acid and a vitamin.

19 . The process according to claim 17 , wherein the physiologically active substance is at least one selected from an insulin, an insulin-like growth factor, transferrin and albumin.

20 . The process according to claim 14 or 15 , wherein the glycoprotein composition is an antibody composition.

21 . A method for naturalizing a cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out in a serum-free medium, which comprises inoculating the cell into a medium for naturalization to give a cell density of 1×10 5 to 1×10 6 cells/ml.

22 . A method for obtaining a clone in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, which comprises naturalizing the cell in a serum-free medium by the method according to claim 21 , and then cloning the cell.

23 . A cell in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the cell is naturalized in a serum-free medium, which is obtainable by the method according to claim 21 .

24 . A clone in which a genomic gene encoding an enzyme relating to a sugar chain modification in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is knocked out, wherein the clone is naturalized in a serum-free medium, which is obtainable by the method according to claim 22 .

25 . The method according to claim 21 or 22 , wherein the serum-free medium is a protein-free medium,

26 . The cell according to claim 23 , wherein the serum-free medium is a protein-free medium.

27 . The clone according to claim 24 , wherein the serum-free medium is a protein-free medium.

Assignments (1)
CHANGE OF NAME Recorded Mar 13, 2009
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022396/0508 →